 |
114 Diseases |  |
361 Trials |
|
361 Trials |  |
7200 News |  |
| «12...3738394041424344454647...100101» |
- || Verzenio (abemaciclib) / Eli Lilly
Clinical, Journal: A Case of Liver Abscess during Treatment for Abemaciclib-Induced Interstitial Lung Disease (Pubmed Central) - Jan 21, 2022
The patient's PR was maintained for 18 months after relapse. We report a case of liver abscess during treatment of abemaciclib-induced interstitial lung disease.
- everolimus / Generic mfg.
Trial completion date, Trial termination, Trial primary completion date: Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) - Jan 21, 2022
P2, N=3, Terminated, Sponsor: Emory University
We report a case of liver abscess during treatment of abemaciclib-induced interstitial lung disease. Trial completion date: Nov 2021 --> Jan 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2021 --> Jan 2021; Slow to accrual
- | letrozole / Generic mfg.
New trial: Letrozole in Induction of Abortion of Anembryonic Pregnancy (clinicaltrials.gov) - Jan 20, 2022
P=N/A, N=90, Recruiting, Sponsor: Cairo University
- | letrozole / Generic mfg.
New P4 trial: letrezole: Evaluation of Different Doses of Letrozole in Ectopic Pregnancy (clinicaltrials.gov) - Jan 20, 2022
P4, N=60, Completed, Sponsor: Zagazig University
- || letrozole / Generic mfg.
Clinical, Retrospective data, Review, Journal: Does letrozole treatment have favorable effects on the lipid profile? A systematic review and meta-analysis of randomized clinical trials. (Pubmed Central) - Jan 15, 2022
Taking into account this comparison between groups, in contrast, LDL-C (WMD: -2.50 mg/dL, 95% CI: -9.94, 4.93, p = 0.510) and triglycerides (WMD: -0.89 mg/dL, 95% CI: -6.87 to 5.07, p = 0.768) did not alter. In conclusion, letrozole administration decreased the concentrations of HDL-C and tocal cholesterol, but not of triglycerides and LDL-C.
- | letrozole / Generic mfg.
Preclinical, Journal: Morphology and Serum and Bone Tissue Calcium and Magnesium Concentrations in the Bones of Male Rats Chronically Treated with Letrozole, a Nonsteroidal Cytochrome P450 Aromatase Inhibitor. (Pubmed Central) - Jan 14, 2022
In conclusion, letrozole administration decreased the concentrations of HDL-C and tocal cholesterol, but not of triglycerides and LDL-C. Chronic treatment with letrozole affected cortical bone structure and produced histomorphological changes in male rat bone similar to that observed in the aging processes.
- | letrozole / Generic mfg.
Preclinical, Journal: Ameliorative effects of Cuscuta reflexa and Peucedanum grande on letrozole induced polycystic ovary syndrome in Wistar rats. (Pubmed Central) - Jan 14, 2022
Histopathological examination showed the protective effect of the CRE and PGE indicated by the disappearance of ovarian cyst. The study demonstrated that the CRE and PGE either alone or in combination hold a significant effect in letrozole induced PCOS rat models and could be useful in the management of reproductive and metabolic disorders related to PCOS.
- | letrozole / Generic mfg.
Journal: Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity. (Pubmed Central) - Jan 14, 2022
Our GWAS findings confirm that steady-state letrozole plasma concentrations are partially determined by germline polymorphisms that affect CYP2A6 activity, including variants near rs7937 such as the intronic rs56113850 variant. Further research is needed to confirm whether rs56113850 directly affects CYP2A6 activity and to integrate nonexonic variants into CYP2A6 phenotypic activity prediction systems.
- || Ibrance (palbociclib) / Pfizer
Clinical, Journal, Real-world evidence: Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice. (Pubmed Central) - Jan 14, 2022
P=N/A
This real-world analysis demonstrated that HR+/HER2‒ MBC patients were more likely to respond to PAL+LET compared to LET. These findings further showed the effectiveness of PAL+LET therapy in the real-world setting and support the combination as a standard of care for MBC.
- || letrozole / Generic mfg.
Clinical, Review, Journal: Androgens and Adult Neurogenesis in the Hippocampus. (Pubmed Central) - Jan 14, 2022
Although direct exposure to androgens in adult or middle age does not significantly influence neurogenesis in female rodents, the aromatase inhibitor letrozole enhances neurogenesis in the hippocampus of middle-aged female mice...Collectively, the research indicates that the ability of androgens to enhance hippocampal neurogenesis in adult rodents is dependent on dose, androgen type, sex, duration, and age. We discuss these findings and how androgens may be influencing neuroprotection, via neurogenesis in the hippocampus, in the context of health and disease.
- || Cetrotide (cetrorelix) / EMD Serono
Clinical, Journal: Pregnancy outcomes following different protocols of controlled ovarian hyperstimulation in couples undergoing intrauterine insemination. (Pubmed Central) - Jan 13, 2022
Our observations show that increased numbers of preovulatory follicles or endometrium thickness do not necessarily improve pregnancy outcomes, as pregnancy outcomes are also subjected to the type of COH utilized agent. In this regard, letrozole produced fewer preovulatory follicles, and did not significantly increase endometrium thickness, but significantly improved pregnancy outcomes in comparison to CC and cetrorelix acetate.
- |||| Ibrance (palbociclib) / Pfizer
Trial completion: PALLET: A Phase II Randomized Study Evaluating the Biological and Clinical Effects of the Combination of Palbociclib With Letrozole as Neoadjuvant Therapy in Post-Menopausal Women With Estrogen-Receptor Positive Primary Breast Cancer (clinicaltrials.gov) - Jan 13, 2022
P2, N=307, Completed, Sponsor: NSABP Foundation Inc
In this regard, letrozole produced fewer preovulatory follicles, and did not significantly increase endometrium thickness, but significantly improved pregnancy outcomes in comparison to CC and cetrorelix acetate. Active, not recruiting --> Completed
- | Ibrance (palbociclib) / Pfizer
New P2 trial, Liquid biopsy, Metastases, Biopsy: ICRG0201: Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies. (clinicaltrials.gov) - Jan 12, 2022
P2, N=80, Not yet recruiting, Sponsor: International Cancer Research Group, United Arab Emirates
- | letrozole / Generic mfg.
Enrollment open, Trial initiation date: NCI-2021-12428: Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer (clinicaltrials.gov) - Jan 12, 2022
P4, N=60, Recruiting, Sponsor: University of Washington
Active, not recruiting --> Completed Not yet recruiting --> Recruiting | Initiation date: Jun 2022 --> Feb 2022
- | Imlygic (talimogene laherparepvec) / Amgen
Trial completion date, Trial primary completion date: T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer (clinicaltrials.gov) - Jan 12, 2022
P1b, N=25, Recruiting, Sponsor: University of California, San Francisco
Not yet recruiting --> Recruiting | Initiation date: Jun 2022 --> Feb 2022 Trial completion date: Feb 2022 --> Apr 2023 | Trial primary completion date: Feb 2022 --> Apr 2023
- | Herceptin (trastuzumab) / Roche, Nerlynx (neratinib) / Puma
Trial completion date, Trial initiation date, Trial primary completion date: Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers (clinicaltrials.gov) - Jan 12, 2022
P2, N=48, Not yet recruiting, Sponsor: Ruth O'Regan
Trial completion date: Feb 2022 --> Apr 2023 | Trial primary completion date: Feb 2022 --> Apr 2023 Trial completion date: Aug 2022 --> Aug 2024 | Initiation date: Jun 2021 --> Sep 2022 | Trial primary completion date: Jun 2022 --> Aug 2023
- ||| lerociclib (G1T38) / Walvax, Pepper Bio
Enrollment open, Metastases: A Study of Lerociclib in Participants With Advanced Breast Cancer (clinicaltrials.gov) - Jan 12, 2022
P2, N=100, Recruiting, Sponsor: EQRx, Inc.
Trial completion date: Aug 2022 --> Aug 2024 | Initiation date: Jun 2021 --> Sep 2022 | Trial primary completion date: Jun 2022 --> Aug 2023 Not yet recruiting --> Recruiting
- || letrozole / Generic mfg.
Clinical, Journal: Genomic aberrations and late recurrence in postmenopausal women with hormone receptor-positive early breast cancer: Results from the SOLE Trial. (Pubmed Central) - Jan 11, 2022
Postmenopausal women with hormone receptor-positive early breast cancer harboring FGFR1 CNG had an increased risk of late recurrence despite extended therapy. FGFR1 CNG may represent a useful prognostic biomarker for late recurrence and a therapeutic target.
- || letrozole / Generic mfg.
Clinical, Journal: Breast Cancer Index predicts extended endocrine benefit to individualize selection of HR+ early stage breast cancer patients for 10 years of endocrine therapy. (Pubmed Central) - Jan 11, 2022
BCI (H/I) predicted preferential benefit from 5 vs 2.5 years of EET and identified patients with improved outcomes from completing 10 years of adjuvant endocrine therapy. Findings expand the clinical utility of BCI (H/I) to a broader range of patients and beyond prognostic risk factors as a predictive endocrine response biomarker for early stage HR+ breast cancer.
- | letrozole / Generic mfg.
Preclinical, Journal: Letrozole-Induced Polycystic Ovary Syndrome Attenuates Cystathionine-β Synthase mRNA and Protein Abundance in the Ovaries of Female Sprague Dawley Rats. (Pubmed Central) - Jan 11, 2022
Findings expand the clinical utility of BCI (H/I) to a broader range of patients and beyond prognostic risk factors as a predictive endocrine response biomarker for early stage HR+ breast cancer. These data demonstrate that letrozole-induced PCOS Sprague Dawley rats temporally decrease the ovarian abundance of Cbs mRNA and protein in the early stages of PCOS.
- | Ibrance (palbociclib) / Pfizer
Trial completion, Trial completion date, Combination therapy, Metastases: PALEO: Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer (clinicaltrials.gov) - Jan 11, 2022
P2, N=78, Completed, Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials Unit
These data demonstrate that letrozole-induced PCOS Sprague Dawley rats temporally decrease the ovarian abundance of Cbs mRNA and protein in the early stages of PCOS. Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Dec 2021
- ||| Imfinzi (durvalumab) / AstraZeneca
Trial termination, Combination therapy: Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer (clinicaltrials.gov) - Jan 11, 2022
P2, N=17, Terminated, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Dec 2021 Active, not recruiting --> Terminated; lost funding
- | metformin / Generic mfg., letrozole / Generic mfg.
Journal: Turmeric extract alleviates endocrine-metabolic disturbances in letrozole-induced PCOS by increasing adiponectin circulation: A comparison with Metformin. (Pubmed Central) - Jan 11, 2022
These changes were linked to lower levels of circulating adiponectin and were reversed when treated Turmeric extract. By altering circulating androgen-adiponectin balance, the data implies that Turmeric extract alleviates endocrine-metabolic abnormalities and inflammation-related comorbidities associated with LET-induced PCOS.
- letrozole / Generic mfg.
Co-treatment with letrozole during ovarian stimulation for IVF|ICSI -- a systematic review and meta-analysis () - Jan 11, 2022 - Abstract #Fertility2022Fertility_331;
Letrozole reduces serum oestradiol by inhibiting the aromatase enzyme and has growing clinical indications in fertility treatments. The available evidence of letrozole's role in ovarian stimulation for IVF/ICSI was assessed concerning pregnancy outcomes with a systematic search performed up until August 2021, including 31 studies with 3,952 women.
- letrozole / Generic mfg.
Does adjuvant letrozole during ovarian stimulation for IVF reduce the need for luteal support? Arandomized controlled trial () - Jan 11, 2022 - Abstract #Fertility2022Fertility_214;
These data suggest that cotreatment with letrozole can reduce the need for luteal phase support, allowing for example fresh transfer after agonist triggering. The impact on the endometrium requires further assessment.
- || Ziihera (zanidatamab-hrii) / Jazz
Enrollment open: A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC) (clinicaltrials.gov) - Jan 11, 2022
P2, N=17, Recruiting, Sponsor: M.D. Anderson Cancer Center
The impact on the endometrium requires further assessment. Not yet recruiting --> Recruiting
- | letrozole / Generic mfg.
New P4 trial: NCI-2021-12428: Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer (clinicaltrials.gov) - Jan 11, 2022
P4, N=60, Not yet recruiting, Sponsor: University of Washington
- ||| Kisqali (ribociclib) / Novartis
Trial completion date, Combination therapy, Metastases: MONALEESA-7: Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer (clinicaltrials.gov) - Jan 10, 2022
P3, N=672, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial completion date: Dec 2021 --> Jun 2022
- | letrozole / Generic mfg.
Journal: Mitochondrial stress adaptation promotes resistance to aromatase inhibitor in human breast cancer cells via ROS/calcium up-regulated amphiregulin-estrogen receptor loop signaling. (Pubmed Central) - Jan 8, 2022
Long-term mitochondrial inhibitor treatments-mediated mitochondrial stress adaptation could induce letrozole resistance...Moreover, mitochondrial stress adaptation-increased intracellular levels of reactive oxygen species (ROS) and calcium were shown to induce AREG expression and secretion. In conclusion, our results support the claim that mitochondrial stress adaptation contributes to AI resistance via ROS/calcium-mediated AREG-ERα loop signaling and provide possible treatment targets for overcoming AI resistance.
- || Ibrance (palbociclib) / Pfizer
Clinical, Journal, Real-world evidence: Effectiveness and Safety of Palbociclib plus Endocrine Therapy in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Real-World Results. (Pubmed Central) - Jan 7, 2022
This study provides data from a real-world setting that match the results of previous studies in terms of effectiveness (i.e., progression-free survival) when palbociclib plus endocrine therapy was used as second- or third-line treatment. Palbociclib had appropriate tolerability and a profile of easily manageable adverse effects, with none of the patients suspending their treatment because of toxic effects.
- || letrozole / Generic mfg., tamoxifen / Generic mfg.
Clinical, Journal: Endometrial Surveillance in Tamoxifen and Letrozole Treated Breast Cancer Patients. (Pubmed Central) - Jan 7, 2022
Tamoxifen and letrozole did not increase the risk of endometrial cancer in premenopausal patients. Breast Cancer (BC) patients on tamoxifen or letrozole might need a pre-treatment endometrial evaluation and explanation of alarming symptoms to guide further endometrial surveillance.
- | samotolisib (LY3023414) / Eli Lilly
Trial completion date, Metastases: A Study of LY3023414 in Participants With Advanced Cancer (clinicaltrials.gov) - Jan 6, 2022
P1, N=156, Active, not recruiting, Sponsor: Eli Lilly and Company
Breast Cancer (BC) patients on tamoxifen or letrozole might need a pre-treatment endometrial evaluation and explanation of alarming symptoms to guide further endometrial surveillance. Trial completion date: Oct 2021 --> Jan 2022
- | letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
Trial completion date: Effect of Aromatase Inhibitor Therapy on Blood Vessel Function in Postmenopausal Women With Breast Cancer (clinicaltrials.gov) - Jan 6, 2022
P=N/A, N=109, Active, not recruiting, Sponsor: Mayo Clinic
Trial completion date: Oct 2021 --> Jan 2022 Trial completion date: Sep 2021 --> Sep 2022
- | Ibrance (palbociclib) / Pfizer
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, HEOR, Patient reported outcomes, Metastases: PRECYCLE: Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy (clinicaltrials.gov) - Jan 6, 2022
P4, N=532, Terminated, Sponsor: Palleos Healthcare GmbH
Trial completion date: Sep 2021 --> Sep 2022 N=960 --> 532 | Trial completion date: Jun 2027 --> Dec 2021 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2027 --> Dec 2021; Due to COVID-19 pandemic, study cannot be finished in planned timeframe.
- |||| Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: Lenvatinib+Letrozole Versus Fulvestrant in Metastatic ER+/HER2- Breast Cancer, Post Progression on Al + CDK4/6 Inhibitor (clinicaltrials.gov) - Jan 6, 2022
P2, N=120, Not yet recruiting, Sponsor: National University Hospital, Singapore
- | pictilisib (GDC-0941) / Roche
Journal: New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells. (Pubmed Central) - Jan 5, 2022
An array of newly synthesized thieno[3,2-d]pyrimidine-based derivatives and thienotriazolopyrimidines hybridized with some pharmacophoric anticancer fragments were designed, synthesized and assessed for their in vitro antiproliferative activity against MCF-7 and MDA-MB-231 breast cancer cell lines using erlotinib and pictilisib as reference standards in the MTT assay...Further mechanistic evidences for their anticancer activities were provided by screening the most potent compounds against MCF-7 and/or MDA-MB-231 cells for EGFR and ARO inhibitory activities using erlotinib and letrozole as reference standards respectively...Docking experiments on EGFR and ARO enzymes supported their in vitro results. Thus, the thienotriazolopyrimidines 11b and 12 showing good EGFR inhibition and the thieno[3,2-d]-pyrimidine derivatives 3b and 9d, eliciting the best ARO inhibition activity, can be considered as new candidates as anti-breast cancer agents that necessitate further development.
- | letrozole / Generic mfg.
Journal: Dedifferentiation in Breast Metastasis of Endometrial Carcinoma: A Diagnostic Dilemma. (Pubmed Central) - Jan 4, 2022
Mastectomy revealed a poorly differentiated malignant tumor with morphology and immunophenotype (including loss of ARID1A and ARID1B immunoreactivity) consistent with undifferentiated endometrial carcinoma with no residual low-grade component. Awareness of the phenomenon of dedifferentiation of endometrial carcinoma in a metastatic site is important to avoid misdiagnosis as a primary breast cancer or metastasis from another primary site.
- || Ibrance (palbociclib) / Pfizer
Clinical, Journal, HEOR, Real-world evidence: Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2- metastatic breast cancer in US real-world clinical practice. (Pubmed Central) - Jan 4, 2022
P=N/A
Awareness of the phenomenon of dedifferentiation of endometrial carcinoma in a metastatic site is important to avoid misdiagnosis as a primary breast cancer or metastasis from another primary site. In this "real-world" population of patients with HR+/HER2- MBC, palbociclib in combination with endocrine therapy was associated with improved survival outcomes compared with patients treated with letrozole alone in the first-line setting.
- | letrozole / Generic mfg.
Journal: Electroacupuncture to Improve Endometrial Receptivity and Folliculogenesis in Polycystic Ovary Syndrome. (Pubmed Central) - Jan 4, 2022
The addition of EA to letrozole therapy improved folliculogenesis, RI, PI, and endometrial thickness in patients with PCOS. Further studies are needed to gain a better understanding of the dosage and timing of this therapy and its potential synergy with other current treatments.
- || Prolia (denosumab) / Amgen, Daiichi Sankyo
Clinical, Journal: Adherence to bone health guidelines in patients with hormone receptor-positive early breast cancer: Status and clinical impact in a Swiss cohort experience. (Pubmed Central) - Jan 4, 2022
Alongside calcium and vitamin D3 supplementation, bisphosphonates and denosumab are well-known options for improving outcomes in bone health and breast cancer prognosis...The most frequent tumor characteristics were tumor size of pT1-pT2 (N = 53, 77.9%) and treatment with letrozole (N = 35, 51.5%), followed by tamoxifen as a switch strategy (N = 27, 40.3%)...The adherence to bone health guidelines was satisfactory but still suboptimal. Clinicians should strictly adhere to the current bone health guidelines to ensure the best possible prevention of BREs and maintain bone health and cancer prognosis in patients with ER + eBC.
- | letrozole / Generic mfg.
Journal: In Silico Molecular Interaction Studies of Chitosan Polymer with Aromatase Inhibitor: Leads to Letrozole Nanoparticles for the Treatment of Breast Cancer. (Pubmed Central) - Jan 1, 2022
Clinicians should strictly adhere to the current bone health guidelines to ensure the best possible prevention of BREs and maintain bone health and cancer prognosis in patients with ER + eBC. Results obtained from the in silico and in vitro studies suggest that Letrozole loaded nanoparticles are ideal for breast cancer treatment.
- || letrozole / Generic mfg.
Retrospective data, Review, Journal, Combination therapy: Effects of using letrozole in combination with the GnRH antagonist protocol for patients with poor ovarian response: a meta-analysis. (Pubmed Central) - Jan 1, 2022
Moreover, letrozole co-treatment aslo can reduce the economic burden of poor responders during the GnRH antagonist cycle. Nevertheless, large-scale and multi-center randomized controlled trials are needed to further evaluate the efficacy of adjunctive letrozole administration in the GnRH antagonist protocol.
- || letrozole / Generic mfg., clomifene citrate / Generic mfg.
Clinical, Journal: Response to ovulation induction treatments in women with polycystic ovary syndrome as a function of serum anti-Müllerian hormone levels. (Pubmed Central) - Jan 1, 2022
In PCOS, increasing serum AMH levels are associated with lower probability of RT to oral agents. Our findings constitute a valuable tool for the clinician when counseling PCOS patients and designing a personalized ovulation induction treatment strategy.
- || letrozole / Generic mfg., clomifene citrate / Generic mfg.
Clinical, Journal: Can methods of artificial intelligence aid in optimizing patient selection in patients undergoing intrauterine inseminations? (Pubmed Central) - Jan 1, 2022
Among the compared methods, the random forest and PLS models demonstrated superior performance in predicting the clinical outcome of IUI. With additional research and clinical validation, AI methods may be successfully used in improving patient selection and consequently lead to better clinical results.
- fulvestrant / Generic mfg.
QUALITY OF LIFE OF THERAPIES FOR HORMONE RECEPTOR POSITIVE ADVANCED/METASTATIC BREAST CANCER (HR+/HER2- MBC): REGULATORY ASPECTS AND CLINICAL IMPACT IN EUROPE ([VIRTUAL]) - Dec 31, 2021 - Abstract #AIOM2021AIOM_35;
An effort should be done from all the stakeholders to increase the visibility of the HRQoL results in order to allow an increasing consideration in the approval process to make QoL data more easily and visibly available for the clinician and the patients. The evaluation should be reflected in the SmPC in order to increase the amount of information provided to the physician.
- Ibrance (palbociclib) / Pfizer
DRUG-DRUG INTERACTIONS BETWEEN PALBOCICLIB AND PROTON PUMP INHIBITORS MAY SIGNIFICANTLY AFFECTCLINICAL OUTCOME OF METASTATIC BREAST CANCER PATIENTS ([VIRTUAL]) - Dec 31, 2021 - Abstract #AIOM2021AIOM_18;
The present study demonstrates that concomitant use of PPIs in mBC patients treated withpalbociclib has a detrimental effect on PFS. Therefore, it is recommended to prescribe PPI withcaution in these patients, or administering H2-antagonists or PPI for very short periods.
- Kisqali (ribociclib) / Novartis
EFFICACY AND SAFETY OF FIRST-LINE RIBOCICLIB (RIB) COMBINED WITH LETROZOLE (LET) IN POSTMENOPAUSAL PATIENTS WITH HORMONE RECEPTOR–POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2–NEGATIVE (HER2–) ADVANCED BREAST CANCER (ABC): RESULTS FROM PHASE IIIB BIOITALEE STUDY (Emerald room [VIRTUAL]) - Dec 31, 2021 - Abstract #AIOM2021AIOM_7;
P3
Therefore, it is recommended to prescribe PPI withcaution in these patients, or administering H2-antagonists or PPI for very short periods. Results from BioItaLEE confirm the safety and efficacy profile of RIB+LET as a first-line treatment in postmenopausal women with HR+, HER2– ABC.
- letrozole / Generic mfg., tamoxifen / Generic mfg.
EXTENDED THERAPY WITH LETROZOLE AS ADJUVANT TREATMENT OF POSTMENOPAUSAL PATIENTS WITH EARLY-STAGE BREAST CANCER: A RANDOMISED, PHASE 3 TRIAL OF THE GRUPPO ITALIANO MAMMELLA (AUDITORIUM [VIRTUAL]) - Dec 31, 2021 - Abstract #AIOM2021AIOM_1;
P3
Results from BioItaLEE confirm the safety and efficacy profile of RIB+LET as a first-line treatment in postmenopausal women with HR+, HER2– ABC. In post-menopausal breast cancer patients treated with 2-3 years of tamoxifen, extended treatment with 5 years of letrozole resulted in a significant and clinically meaningful improvement in both DFS and OS compared to the duration of 2-3 years of letrozole.
- | metformin / Generic mfg., letrozole / Generic mfg.
Preclinical, Journal: Soy isoflavones alleviate polycystic ovary syndrome in rats by regulating NF- κB signaling pathway. (Pubmed Central) - Dec 30, 2021
After PCOS induction, Soy isoflavones (100 mg/kg) or metformin (Positive control; 500 mg/kg) was administered continuously for 28 days...At the same time, Soy isoflavones treatment inhibit the phosphorylation level of NF-κB p65 and increased the IκBα expression in ovarian tissues of PCOS rats. Overall, Soy isoflavones can improve ovarian morphology and hormone disorders in PCOS rats by inhibiting the activity of NF-κB pathway and enhancing anti-inflammatory and antioxidant capacity.
- | Ibrance (palbociclib) / Pfizer
Preclinical, Journal: Novel Combinatorial Strategy Using Thermal Inkjet Bioprinting, Chemotherapy, and Radiation on Human Breast Cancer Cells; an In-Vitro Cell Viability Assessment. (Pubmed Central) - Dec 27, 2021
Overall, Soy isoflavones can improve ovarian morphology and hormone disorders in PCOS rats by inhibiting the activity of NF-κB pathway and enhancing anti-inflammatory and antioxidant capacity. Based on these results, we suggest that TIB used in in-vitro models could be a feasible strategy to develop and/or test new anticancer drugs.